Uncategorized
Durasert for posterior segment uveitis meets primary efficacy endpoint in phase 3 trial
Durasert, a 3-year treatment for posterior segment uveitis, achieved its primary efficacy endpoint in a second phase 3 trial, pSivida announced in a press release.The insert significantly reduced the recurrence of posterior segment uveitis in patients through 6 months of treatment, with 21.8% of patients in the Durasert treatment group experiencing a recurrence of posterior segment uveitis compared with 53.8% of patients in a sham group (P < .001).